HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults

Waldman, Abigail; Whiting, Dennis; Rani, M. Mary Shanthi; Alam, Murad

doi:10.1097/00042728-900000000-98447

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of complete response in this study (62.2%) was higher than that in previous reports (43.7% in a study by Waldman et al 3 and 46.7% in a study by Yang et al 4 ) that investigated the efficacy of a 4-valent HPV vaccine for the treatment of warts. In addition, 15 out of 20 patients with periungual warts had a complete response, and there was no nail deformity after complete resolution in this study.…”

Section: Nonavalent Human Papilloma Virus Vaccine For the Treatment O...contrasting

confidence: 72%

Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study

Shin

Son

Lee

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Nonavalent Human Papilloma Virus Vaccine For the Treatment O...contrasting

confidence: 72%

Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study

Shin

Son

Lee

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…It has been observed that following the clearance of an initial infection with HPV, subsequent infections with the same strain of HPV are uncommon 22,23 . This suggests that a strain‐specific immunity provides protection, indicating a need for the development of strain‐specific anti‐HPV therapy 2 .…”

Section: Discussionmentioning

confidence: 99%

“…Various case reports and series as well as one study in the past have demonstrated the effectiveness of the quadrivalent HPV vaccine in clearing extragenital warts. The effectiveness of HPV‐vaccination in extragenital warts is thought to be due to the cross‐immunization provided by the quadrivalent HPV strains and their L1 proteins against the extragenital strains 23‐26 . However, the data on its effectiveness are still speculative and require further exploration.…”

Section: Discussionmentioning

confidence: 99%

A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children

Mohta¹,

Kushwaha²,

Gautam³

et al. 2020

Pediatric Dermatology

View full text Add to dashboard Cite

Background: Intralesional vitamin D3 has recently emerged as a new treatment for cutaneous warts. The use of the measles, mumps, and rubella (MMR) vaccine for this purpose is an established modality. However, relevant data on the efficacy of either the MMR vaccine or vitamin D3 as immunotherapy for cutaneous warts in the pediatric population are limited. Objectives: To compare the efficacy and safety of intralesional injections of MMR vaccine to intralesional injections of vitamin D3 in children aged 8-16 years with multiple warts. Methods: A total of 74 children were randomly allocated into two groups. Group A patients received intralesional MMR vaccine into the largest wart, and group B received intralesional vitamin D3 into the largest wart. The injections were repeated every 4 weeks until clearance or for a maximum of three treatments. After the last injection, children were followed up every 2 weeks for 3 months, and at the sixth month, a final clinical assessment was conducted. Results: Of 74 children, 60 completed the study, with 30 children in each group. Complete clearance of the injected wart was observed in 26 (86.67%) patients in the MMR group (group A) and 23 (76.7%) patients in the vitamin D3 group (group B). Distant warts cleared in 23 (76.7%) patients in group A compared to 20 (66.6%) patients in group B. There was no significant difference between groups. No recurrence was seen in group A, whereas two (6.6%) children in group B exhibited recurrence in the ensuing 6-month follow-up. The most common adverse events were injection site pain and swelling. Conclusion: Both intralesional MMR and vitamin D3 are safe, generally well-tolerated, and equally effective in children for the treatment of cutaneous warts.

show abstract

“…To the Editor:Verruca vulgaris (VV), a common, benign neoplasm of the skin caused by human papillomavirus (HPV), is a leading indication for dermatology visits, but treatment remains challenging. 1,2 VV are due to HPV types 1, 2, and 4, which are not covered by HPV vaccines. Recent studies document VV resolution following HPV vaccination, but do not consider that most individuals clear VV spontaneously.…”

Section: Vaccination Against Human Papillomavirus Is Not Associated W...mentioning

confidence: 99%

“…Recent studies document VV resolution following HPV vaccination, but do not consider that most individuals clear VV spontaneously. [1][2][3][4] This retrospective cohort study, the first to include an unvaccinated group to control for VV natural history, aims to assess whether HPV vaccination is associated with VV resolution.…”

Section: Vaccination Against Human Papillomavirus Is Not Associated W...mentioning

confidence: 99%

Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds

Kost¹,

Deutsch²,

Zhu³

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults

Cited by 4 publications

References 0 publications

Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study

Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study

A comparative study of the efficacy and safety of intralesional measles, mumps, and rubella vaccine versus intralesional vitamin D3 for the treatment of warts in children

Vaccination against human papillomavirus is not associated with resolution of verruca vulgaris in immunocompetent 9- to 21-year olds

Contact Info

Product

Resources

About